Streetbeat News

HURA

TuHURA Biosciences, Inc.

http://www.tuhurabio.com

Industry

Biotechnology

TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.

Open

3.36

Mkt cap

141M

Volume

128K

High

3.56

P/E Ratio

-9.00

52-wk high

14.60

Low

3.32

Div yield

N/A

52-wk low

2.83

TuHURA Biosciences, Inc. participated in the Virtual Investor 'Top 5 for ‘25' On-Demand Conference, showcasing its Phase 3 immune-oncology technologies.

Portfolio Pulse from

February 19, 2025 | 2:15 pm

In Friday's after-market session, several healthcare stocks experienced significant price movements. Healthcare Triangle, Mira Pharmaceuticals, MEI Pharma, TuHURA Biosciences, P3 Health Partners, and OKYO Pharma saw notable gains, while Aclaris Therapeutics, Beyond Air, Qualigen Therapeutics, Nuwellis, Compass Pathways, and Helius Medical Tech experienced declines.

Portfolio Pulse from Benzinga Insights

October 25, 2024 | 8:31 pm

In Tuesday's after-market session, several healthcare stocks experienced significant price movements. Protagenic Therapeutics, Talphera, Context Therapeutics, Fortrea Holdings, Genelux, and ENDRA Life Sciences saw gains, while TELA Bio, Ensysce Biosciences, Genprex, Allakos, Sensei Biotherapeutics, and TuHURA Biosciences experienced declines.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 8:31 pm

In Tuesday's pre-market session, several health care stocks experienced significant movements. Ensysce Biosciences and Genprex saw substantial gains, while GRI Bio and Sensei Biotherapeutics faced notable declines. Medpace Holdings also declined following its Q3 earnings release.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 12:07 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Ensysce Biosciences and Genprex saw substantial gains, while GRI Bio and Sensei Biotherapeutics faced notable declines. Medpace Holdings also saw a decrease following its Q3 earnings report.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 12:07 pm

Several healthcare stocks experienced significant intraday movements on Monday. Genprex, Inspire Veterinary, and BioVie saw substantial gains, while TC BioPharm, Meihua Intl Medical Techs, and Gritstone Bio faced notable declines.

Portfolio Pulse from Benzinga Insights

October 21, 2024 | 4:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.